ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Georg Kääb contributed 47 entries already.
The aim of this unique initiative, part of the so-called Generation Study, is to sequence the genomes of 100,000 newborns in England to enable the early detection of over 200 selected conditions and to accelerate the treatment of rare diseases.
The Dutch-Swiss company with operations also in Zurich, Switzerland, has raised US$73m in a Series B and will continue to expand its AI research, sales, and operations teams. The new announcement comes around a year after raising €21.92m in a Series A funding round.
Another strong financing round for Belgian Agomab NV. Sanofi is joining the band wagon of targeting the TGFbeta receptor.
Rentschler Biopharma announces largest single investment in the higher double-digit range at its headquarters in Germany for construction of a new buffer media facility in Laupheim.
Roche drops a third Alzheimer’s candidate this year, leaving a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
The region regulated by the European Medicines Agency (EMA) has been the most proactive globally in the early adoption of biosimilars. By February 2023, it had approved around 75 products containing them. The distribution of such compounds within Europe, however, has been uneven, with some countries offering more market opportunities than others. Beyond Europe, few producers have a strategy for the Middle East and/or Africa, and India and South Korea could soon jump in to fill the gap.
Immunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline.
A current Nature study specifies the most competitive health biotech sectors worldwide and puts Switzerland at the top, Sweden second and the USA third. Does the new math convince?
European Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS).
Navinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration, a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.